To investigate the impact of the COVID-19 pandemic on the route to diagnosis, disease stage at presentation, and patient outcomes in multiple myeloma (MM), highlighting the significance of these findings for future patient care.
Key Findings:
32% of myeloma diagnoses in 2013 were made via emergency care, linked to shorter survival, emphasizing the need for timely diagnosis.
During early COVID-19, urgent cancer referrals fell by 70%, leading to an estimated 430,000 fewer patients referred for suspected cancer, highlighting the pandemic's impact on cancer care.
No significant differences in age, gender ratio, or disease characteristics were found between pre-COVID and post-COVID cohorts, suggesting consistent patient demographics despite the pandemic.
Interpretation:
The COVID-19 pandemic has exacerbated delays in diagnosing multiple myeloma, potentially leading to worse patient outcomes due to increased disease burden at presentation, necessitating urgent improvements in diagnostic pathways.
Limitations:
The study is limited to a specific geographic area and may not be generalizable; future studies should consider broader populations.
Data collection relied on electronic patient records, which may have incomplete information, suggesting a need for comprehensive data collection methods.
Conclusion:
The pandemic has significantly impacted the diagnosis and management of multiple myeloma, highlighting the urgent need for improved diagnostic pathways and patient care strategies to mitigate these effects.
by Jonathan Carmichael, Frances Seymour, Graham McIlroy, Sarrah Tayabali, Rosie Amerikanou, Sylvia Feyler, Rakesh Popat, Guy Pratt, Christopher Parrish, A. John Ashcroft, Graham H. Jackson, Gordon Cook
